Cholecalciferol in haemodialysis patients: A randomized, double-blind, proof-of-concept and safety study

Nephrology Dialysis Transplantation

Volumn 28, Issue 7, 2013, Pages 1779-1786

  Delanaye, Pierre ^a   Weekers, Laurent ^a   Warling, Xavier ^b   Moonen, Martial ^b   Smelten, Nicole ^c   Médart, Laurent ^b   Krzesinski, Jean Marie ^a   Cavalier, Etienne ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Centre Hospitalier Du Bois de L'Abbaye   (Belgium)

Author keywords

Calcification; Parathormone; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; COLECALCIFEROL; PARATHYROID HORMONE;

ADVERSE OUTCOME; AGED; ARTICLE; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEMODIALYSIS PATIENT; HORMONE BLOOD LEVEL; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VITAMIN BLOOD LEVEL; X RAY ANALYSIS;

CALCIFICATION; PARATHORMONE; VITAMIN D;

AGED; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS; VASCULAR CALCIFICATION; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84879953710     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft001     Document Type: Article

References (43)

1. Cavalier E, Delanaye P, Chapelle JP et al. Vitamin D: current status and perspectives. Clin Chem Lab Med 2009; 47: 120-127
2. Kandula P, Dobre M, Schold JD et al. Vitamin D supplementation in chronic kidney disease: a systematic review and metaanalysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011; 6: 50-62
3. Rutherford WE, Blondin J, Hruska K et al. Effect of 25- hydroxycholecalciferol on calcium absorption in chronic renal disease. Kidney Int 1975; 8: 320-324
4. Witmer G, Margolis A, Fontaine O et al. Effects of 25- hydroxycholecalciferol on bone lesions of children with terminal renal failure. Kidney Int 1976; 10: 395-408
5. Fournier A, Bordier P, Gueris J et al. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25- hydroxycholecalciferol on bone mineralization. Kidney Int 1979; 15: 196-204
6. Cunningham J, Makin H. How important is vitamin D deficiency in uraemia? Nephrol Dial Transplant 1997; 12: 16-18
7. Coen G, Mantella D, Manni M et al. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int 2005; 68: 1840-1848
8. Lambert PW, Stern PH, Avioli RC et al. Evidence for extrarenal production of 1 alpha, 25-dihydroxyvitamin D in man. J Clin Invest 1982; 69: 722-725
9. Jones G. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alphahydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin Dial 2007; 20: 316-324
10. Dusso A, Lopez-Hilker S, Rapp N et al. Extra-renal production of calcitriol in chronic renal failure. Kidney Int 1988; 34: 368-375
11. Melamed ML, Thadhani RI. Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol 2012; 7: 358-365
12. Qaw F, Calverley MJ, Schroeder NJ et al. In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem 1993; 268: 282-292
13. Zehnder D, Bland R, Williams MC et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001; 86: 888-894
14. Jacob AI, Sallman A, Santiz Z et al. Defective photoproduction of cholecalciferol in normal and uremic humans. J Nutr 1984; 114: 1313-1319
15. Gonzalez EA, Sachdeva A, Oliver DA et al. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004; 24: 503-510
16. Del Valle E, Negri AL, Aguirre C et al. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int 2007; 11: 315-321
17. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013
18. Saab G, Young DO, Gincherman Y et al. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007; 105: c132-c138
19. Blair D, Byham-Gray L, Lewis E et al. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr 2008; 18: 375-382
20. Matias PJ, Ferreira C, Jorge C et al. 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 611-618
21. Bhan I, Burnett-Bowie SA, Ye J et al. Clinical measures identify vitamin D deficiency in dialysis. Clin J Am Soc Nephrol 2010; 5: 460-467
22. Matias PJ, Jorge C, Ferreira C et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010; 5: 905-911
23. Wang AY, Lam CW, Sanderson JE et al. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am J Clin Nutr 2008; 87: 1631-1638
24. Drechsler C, Verduijn M, Pilz S et al. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2011; 26: 1024-1032
25. Fiedler R, Dorligjav O, Seibert E et al. Vitamin D deficiency, mortality, and hospitalization in hemodialysis patients with or without protein-energy wasting. Nephron Clin Pract 2011; 119: c220-c226
26. Jean G, Lataillade D, Genet L et al. Impact of hypovitaminosis D and alfacalcidol therapy on survival of hemodialysis patients: results from the French ARNOS study. Nephron Clin Pract 2011; 118: c204-c210
27. Pilz S, Iodice S, Zittermann A et al. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011; 58: 374-382
28. Barreto DV, Barreto FC, Liabeuf S et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1128-1135
29. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1-130
30. Gauci C, Moranne O, Fouqueray B et al. Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol 2008; 19: 1592-1598
31. Kauppila LI, Polak JF, Cupples LA et al. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 1997; 132: 245-250
32. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281
33. Jean G, Terrat JC, Vanel T et al. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant 2008; 23: 3670-3676
34. Jean G, Souberbielle JC, Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 2009; 24: 3799-3805
35. Tokmak F, Quack I, Schieren G et al. High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 2008; 23: 4016-4020
36. Jakopin E, Pecovnik BB, Ekart R et al. High-dose cholecalciferol supplementation for vitamin D deficiency in haemodialysis patients. J Int Med Res 2011; 39: 1099-1106
37. Wasse H, Huang R, Long Q et al. Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis. Am J Clin Nutr 2012; 95: 522-528
38. Ritter CS, Armbrecht HJ, Slatopolsky E et al. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 2006; 70: 654-659
39. Sardiwal S, Gardham C, Coleman AE et al. Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int 2012; 82: 100-105
40. Mathew S, Lund RJ, Chaudhary LR et al. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008; 19: 1509-1519
41. Honkanen E, Kauppila L, Wikstrom B et al. Calcification outcome in renal disease (CORD) study-two years progression and prognostic value of abdominal aortic calcification in dialysis and after renal transplantation. Nephrol Dial Transplant Plus Suppl 2008; 1: ii212
42. Fournier A, Harbouche L, Mansour J et al. Impact of calcium and vitamin D therapy on arterial and cardiac disease in young adults with childhood-onset end stage renal disease. Nephrol Dial Transplant 2007; 22: 956-957
43. London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620